The challenge of enteric fever

Journal of Infection

Volumn 68, Issue SUPPL1, 2014, Pages

  Waddington, Claire S ^a   Darton, Thomas C ^a   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Challenge studies; Controlled human infection; Disease control; Enteric fever; Paratyphoid; S. Paratyphi; S. Typhi; Typhoid; Vaccine

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BACTERIAL DNA; BACTERIUM LIPOPOLYSACCHARIDE; CIPROFLOXACIN; CVD 1902; CVD 908; CVD 909; INACTIVATED VACCINE; LIPOPOLYSACCHARIDE DIPHTHERIA TOXIN CONJUGATE VACCINE; LIVE VACCINE; M01ZH09; MENINGOCOCCUS POLYSACCHARIDE VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TY800; TYPHOID PARATYPHOID VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VI CRM197; VI DIPTHERIA TOXOID; VI TETANUS TOXOID; VIPS PROTEIN CONJUGATE VACCINE;

ABDOMINAL TENDERNESS; ACUTE DISEASE; AFRICA; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; ASIAN; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATION; BILE DUCT CANCER; BLOOD CULTURE; BLOODSTREAM INFECTION; BONE MARROW CULTURE; CHOLECYSTECTOMY; CLINICAL STUDY; DISEASE CARRIER; DISEASE MODEL; DISEASE SEVERITY; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DNA DETERMINATION; DRUG CAPSULE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENDEMIC DISEASE; EPIDEMIC; EXPERIMENTAL STUDY; FECES; FOOD HANDLING; GALLSTONE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HYGIENE; IMMUNOBIOLOGY; IMMUNOGENICITY; INCIDENCE; INTERMETHOD COMPARISON; LICENSING; LOW DRUG DOSE; MACULOPAPULAR RASH; MORTALITY; NONHUMAN; PARATYPHOID FEVER; PATHOGEN CLEARANCE; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PREVALENCE; RISK FACTOR; SALMONELLA PARATYPHI B; SALMONELLA PARATYPHI C; SALMONELLA TYPHI; SANITATION; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SINGLE DRUG DOSE; TRAVEL; TYPHOID FEVER; VACCINATION; VACCINEMIA; WIDAL REACTION;

CHALLENGE STUDIES; CONTROLLED HUMAN INFECTION; DISEASE CONTROL; ENTERIC FEVER; PARATYPHOID; S. PARATYPHI; S. TYPHI; TYPHOID; VACCINE;

ANTI-BACTERIAL AGENTS; HUMANS; SALMONELLA VACCINES; SANITATION; TYPHOID FEVER;

EID: 84889671191     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.09.013     Document Type: Article

References (165)

1. Groschel D.H., Hornick R.B. Who introduced typhoid vaccination: Almroth Write or Richard Pfeiffer?. Rev Infect Dis 1981, 3(6):1251-1254.
2. Buckle G.C., Walker C.L., Black R.E. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. J Glob Health 2012, 2(1):10401.
3. Crump J.A., Mintz E.D. Global trends in typhoid and paratyphoid fever. Clin Infect Dis 2010, 50(2):241-246.
4. Woods C.W., Murdoch D.R., Zimmerman M.D., Glover W.A., Basnyat B., Wolf L., et al. Emergence of Salmonella enterica serotype paratyphi A as a major cause of enteric fever in Kathmandu, Nepal. Trans R Soc Trop Med Hyg 2006, 100(11):1063-1067.
5. Ochiai R.L., Wang X., von Seidlein L., Yang J., Bhutta Z.A., Bhattacharya S.K., et al. Salmonella paratyphi A rates, Asia. Emerg Infect Dis 2005, 11(11):1764-1766.
6. Patel T.A., Armstrong M., Morris-Jones S.D., Wright S.G., Doherty T. Imported enteric fever: case series from the hospital for tropical diseases, London, United Kingdom. Am J Trop Med Hyg 2010, 82(6):1121-1126.
7. Health Protection Agency Salmonella typhi and Salmonella paratyphi laboratory reports (cases only) 2009, Available from:. http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Salmonella/Epidemio%20logicalData/salmDataTyphi/.
8. Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull World Health Organ 2004, 82(5):346-353.
9. Reddy E.A., Shaw A.V., Crump J.A. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10(6):417-432.
10. Crump J.A., Ram P.K., Gupta S.K., Miller M.A., Mintz E.D. Part I. Analysis of data gaps pertaining to Salmonella enterica serotype typhi infections in low and medium human development index countries, 1984-2005. Epidemiol Infect 2008, 136(4):436-448.
11. Mweu E., English M. Typhoid fever in children in Africa. Trop Med Int Health 2008, 13(4):532-540.
12. Parry C.M., Hien T.T., Dougan G., White N.J., Farrar J.J. Typhoid fever. N Engl J Med 2002, 347(22):1770-1782.
13. Bhutta Z.A. Current concepts in the diagnosis and treatment of typhoid fever. BMJ 2006, 333(7558):78-82.
14. Ochiai R.L., Acosta C.J., Danovaro-Holliday M.C., Baiqing D., Bhattacharya S.K., Agtini M.D., et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ 2008, 86(4):260-268.
15. Levine M.M., Taylor D.N., Ferreccio C. Typhoid vaccines come of age. Pediatr Infect Dis J 1989, 8(6):374-381.
16. Levine M.M., Grados O., Gilman R.H., Woodward W.E., Solis-Plaza R., Waldman W. Diagnostic value of the Widal test in areas endemic for typhoid fever. Am J Trop Med Hyg 1978, 27(4):795-800.
17. Wain J., Diep T.S., Bay P.V., Walsh A.L., Vinh H., Duong N.M., et al. Specimens and culture media for the laboratory diagnosis of typhoid fever. J Infect Dev Ctries 2008, 2(6):469-474.
18. Ackers M.L., Puhr N.D., Tauxe R.V., Mintz E.D. Laboratory-based surveillance of Salmonella serotype typhi infections in the United States: antimicrobial resistance on the rise. J Am Med Assoc 2000, 283(20):2668-2673.
19. Nga T.V., Parry C.M., Le T., Lan N.P., Diep T.S., Campbell J.I., et al. The decline of typhoid and the rise of non-typhoid salmonellae and fungal infections in a changing HIV landscape: bloodstream infection trends over 15 years in southern Vietnam. Trans R Soc Trop Med Hyg 2012, 106(1):26-34.
20. Marks F., Adu-Sarkodie Y., Hunger F., Sarpong N., Ekuban S., Agyekum A., et al. Typhoid fever among children, Ghana. Emerg Infect Dis 2010, 16(11):1796-1797.
21. Obaro S., Lawson L., Essen U., Ibrahim K., Brooks K., Otuneye A., et al. Community acquired bacteremia in young children from central Nigeria-a pilot study. BMC Infect Dis 2011, 11:137.
22. Thriemer K., Ley B., Ame S., von Seidlein L., Pak G.D., Chang N.Y., et al. The burden of invasive bacterial infections in Pemba, Zanzibar. PLoS One 2012, 7(2):e30350.
23. Pohan H.T. Clinical and laboratory manifestations of typhoid fever at Persahabatan Hospital, Jakarta. Acta Med Indones 2004, 36(2):78-83.
24. Dimitrov T., Udo E.E., Albaksami O., Al-Shehab S., Kilani A., Shehab M., et al. Clinical and microbiological investigations of typhoid fever in an infectious disease hospital in Kuwait. J Med Microbiol 2007, 56(Pt 4):538-544.
25. Stuart B., Pullen R. Typhoid fever; clinical analysis of three hundred and sixty cases. Arch Intern Med 1946, 78:629-661.
26. Huckstep R.L. Typhoid fever and other Salmonella infections 1962, Livinstone, Edinburgh.
27. Klotz S.A., Jorgensen J.H., Buckwold F.J., Craven P.C. Typhoid fever. An epidemic with remarkably few clinical signs and symptoms. Arch Intern Med 1984, 144(3):533-537.
28. Dougan G., John V., Palmer S., Mastroeni P. Immunity to salmonellosis. Immunol Rev 2011, 240(1):196-210.
29. Mortimer P.P. Mr N the milker, and Dr Koch's concept of the healthy carrier. Lancet 1999, 353(9161):1354-1356.
30. Houston A.C.L., Otto, Bainbridge F.A., O'Brien R. Discussion on recently acquired knowledge concerning the bionomics of pathogenic organisms and its bearing on the spread of disease. Br Med J Nov. 12, 1910, 2:1499-1506.
31. Marr J.S. Typhoid Mary. Lancet 1999, 353(9165):1714.
32. BBC News Typhoid women were kept in asylum 2008, [05/02/2011]. Available from:. http://news.bbc.co.uk/1/hi/uk/7528045.stm.
33. Merselis J.G., Kaye D., Connolly C.S., Hook E.W. Quantitative bacteriology of the typhoid carrier state. Am J Trop Med Hyg 1964, 13:425-429.
34. Levine M.M., Black R.E., Lanata C. Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area. J Infect Dis 1982, 146(6):724-726.
35. Schioler H., Christiansen E.D., Hoybye G., Rasmussen S.N., Greibe J. Biliary calculi in chronic Salmonella carriers and healthy controls: a controlled study. Scand J Infect Dis 1983, 15(1):17-19.
36. Crawford R.W., Gibson D.L., Kay W.W., Gunn J.S. Identification of a bile-induced exopolysaccharide required for Salmonella biofilm formation on gallstone surfaces. Infect Immun 2008, 76(11):5341-5349.
37. Ramos-Morales F., Prieto A.I., Beuzon C.R., Holden D.W., Casadesus J. Role for Salmonella enterica enterobacterial common antigen in bile resistance and virulence. J Bacteriol 2003, 185(17):5328-5332.
38. Caygill C.P., Hill M.J., Braddick M., Sharp J.C. Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet 1994, 343(8889):83-84.
39. Whitby J.M. Ampicillin in treatment of salmonella typhi carriers. Lancet 1964, 2(7350):71-72.
40. Phillips W.E. Treatment of chronic typhoid carriers with ampicillin. J Am Med Assoc 1971, 217(7):913-915.
41. Hudson S.J., Ingham H.R., Snow M.H. Treatment of Salmonella typhi carrier state with ciprofloxacin. Lancet 1985, 1(8436):1047.
42. Crawford R.W., Rosales-Reyes R., Ramirez-Aguilar Mde L., Chapa-Azuela O., Alpuche-Aranda C., Gunn J.S. Gallstones play a significant role in Salmonella spp. gallbladder colonization and carriage. Proc Natl Acad Sci U S A 2010, 107(9):4353-4358.
43. Dinbar A., Altmann G., Tulcinsky D.B. The treatment of chronic biliary salmonella carriers. Am J Med 1969, 47(2):236-242.
44. Nath G., Singh Y.K., Maurya P., Gulati A.K., Srivastava R.C., Tripathi S.K. Does Salmonella typhi primarily reside in the liver of chronic typhoid carriers?. J Infect Dev Ctries 2010 Feb 3, 4(4):259-261.
45. Sinnott C.R., Teall A.J. Persistent gallbladder carriage of Salmonella typhi. Lancet 1987, 1(8539):976.
46. Patil A.M., Kulkarni M.L., Kulkarni A.M. Baseline Widal titres in healthy children. Indian J Pediatr 2007, 74(12):1081-1083.
47. Johnston W. On the application of the serum diagnosis of typhoid fever to the requirements of public health laboratories. Public Health Pap Rep 1896, 22:248-253.
48. Olsen S.J., Pruckler J., Bibb W., Nguyen T.M., Tran M.T., Sivapalasingam S., et al. Evaluation of rapid diagnostic tests for typhoid fever. J Clin Microbiol 2004, 42(5):1885-1889.
49. Olopoenia L.A., King A.L. Widal agglutination test - 100 years later: still plagued by controversy. Postgrad Med J 2000, 76(892):80-84.
50. Choo K.E., Davis T.M., Ismail A., Tuan Ibrahim T.A., Ghazali W.N. Rapid and reliable serological diagnosis of enteric fever: comparative sensitivity and specificity of Typhidot and Typhidot-M tests in febrile Malaysian children. Acta Trop 1999, 72(2):175-183.
51. Choo K.E., Oppenheimer S.J., Ismail A.B., Ong K.H. Rapid serodiagnosis of typhoid fever by dot enzyme immunoassay in an endemic area. Clin Infect Dis 1994, 19(1):172-176.
52. Duthie R., French G.L. Comparison of methods for the diagnosis of typhoid fever. J Clin Pathol 1990, 43(10):863-865.
53. Hoffman S.L., Flanigan T.P., Klaucke D., Leksana B., Rockhill R.C., Punjabi N.H., et al. The Widal slide agglutination test, a valuable rapid diagnostic test in typhoid fever patients at the Infectious Diseases Hospital of Jakarta. Am J Epidemiol 1986, 123(5):869-875.
54. House D., Wain J., Ho V.A., Diep T.S., Chinh N.T., Bay P.V., et al. Serology of typhoid fever in an area of endemicity and its relevance to diagnosis. J Clin Microbiol 2001, 39(3):1002-1007.
55. Kulkarni M.L., Rego S.J. Value of single Widal test in the diagnosis of typhoid fever. Indian Pediatr 1994, 31(11):1373-1377.
56. Parry C.M., Wijedoru L., Arjyal A., Baker S. The utility of diagnostic tests for enteric fever in endemic locations. Expert Rev Anti Infect Ther 2011, 9(6):711-725.
57. Coleman W., Buxton B.H. The bacteriology of the blood in convalescence from typhoid fever. With a theory of the pathogenesis of the disease. J Med Res 1909, 21(1):83-93.
58. Wain J., Diep T.S., Ho V.A., Walsh A.M., Nguyen T.T., Parry C.M., et al. Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J Clin Microbiol 1998, 36(6):1683-1687.
59. Farooqui B.J., Khurshid M., Ashfaq M.K., Khan M.A. Comparative yield of Salmonella typhi from blood and bone marrow cultures in patients with fever of unknown origin. J Clin Pathol 1991, 44(3):258-259.
60. Gilman R.H., Terminel M., Levine M.M., Hernandez-Mendoza P., Hornick R.B. Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet 1975, 1(7918):1211-1213.
61. Vallenas C., Hernandez H., Kay B., Black R., Gotuzzo E. Efficacy of bone marrow, blood, stool and duodenal contents cultures for bacteriologic confirmation of typhoid fever in children. Pediatr Infect Dis 1985, 4(5):496-498.
62. World Health Organisation Background document: the diagnosis, prevention, and treatment of typhoid fever 2003, WHO, [cited 2010 02/09/2012]. Available from:. http://www.who.int/vaccine_research/documents/en/typhoid_diagnosis.pdf.
63. Handschur M., Karlic H., Hertel C., Pfeilstocker M., Haslberger A.G. Preanalytic removal of human DNA eliminates false signals in general 16S rDNA PCR monitoring of bacterial pathogens in blood. Comp Immunol Microbiol Infect Dis 2009, 32(3):207-219.
64. Zhou L., Pollard A.J. A fast and highly sensitive blood culture PCR method for clinical detection of Salmonella enterica serovar typhi. Ann Clin Microbiol Antimicrob 2010, 9:14.
65. Zhou L., Darton T., Waddington C., Pollard A. Molecular diagnosis of enteric fever; progress and perspectives. Salmonella- Distribution, adaptation, control measures and molecular technologies 2012.
66. Allen H.W. Laboratory methods of diagnosis in typhoid fever. Cal State J Med 1907, 5(3):57-59.
67. Smith J.L., Tennant J. A study of the epidemic of typhoid fever in Belfast, 1898. Br Med J 1899, 1(1987):193-197.
68. Smith C.E. Role of the sanitary privy in the control of typhoid fever. Am J Public Health (N Y) 1920, 10(2):140-141.
69. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec 2008, 83(6):49-59.
70. Mara D.D. Water, sanitation and hygiene for the health of developing nations. Public Health 2003, 117(6):452-456.
71. Siddiqui F.J., Rabbani F., Hasan R., Nizami S.Q., Bhutta Z.A. Typhoid fever in children: some epidemiological considerations from Karachi, Pakistan. Int J Infect Dis 2006, 10(3):215-222.
72. Velema J.P., van Wijnen G., Bult P., van Naerssen T., Jota S. Typhoid fever in Ujung Pandang, Indonesia-high-risk groups and high-risk behaviours. Trop Med Int Health 1997, 2(11):1088-1094.
73. Lin F.Y., Vo A.H., Phan V.B., Nguyen T.T., Bryla D., Tran C.T., et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg 2000, 62(5):644-648.
74. Black R.E., Cisneros L., Levine M.M., Banfi A., Lobos H., Rodriguez H. Case-control study to identify risk factors for paediatric endemic typhoid fever in Santiago, Chile. Bull World Health Organ 1985, 63(5):899-904.
75. Luby S.P., Faizan M.K., Fisher-Hoch S.P., Syed A., Mintz E.D., Bhutta Z.A., et al. Risk factors for typhoid fever in an endemic setting, Karachi, Pakistan. Epidemiol Infect 1998, 120(2):129-138.
76. Saha S.K., Baqui A.H., Hanif M., Darmstadt G.L., Ruhulamin M., Nagatake T., et al. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr Infect Dis J 2001, 20(5):521-524.
77. Karkey A., Aryjal A., Basnyat B., Baker S. Kathmandu, Nepal: still an enteric fever capital of the world. J Infect Dev Ctries 2008, 2(6):461-465.
78. Mermin J.H., Villar R., Carpenter J., Roberts L., Samaridden A., Gasanova L., et al. A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water. J Infect Dis 1999, 179(6):1416-1422.
79. Ryan C.A., Hargrett-Bean N.T., Blake P.A. Salmonella typhi infections in the United States, 1975-1984: increasing role of foreign travel. Rev Infect Dis 1989, 11(1):1-8.
80. Mermin J.H., Townes J.M., Gerber M., Dolan N., Mintz E.D., Tauxe R.V. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med 1998, 158(6):633-638.
81. Steinberg E.B., Bishop R., Haber P., Dempsey A.F., Hoekstra R.M., Nelson J.M., et al. Typhoid fever in travelers: who should be targeted for prevention?. Clin Infect Dis 2004, 39(2):186-191.
82. Health Protection Agency Pilot of enhanced surveillance of enteric fever in England, Wales, and Northern Ireland 2007, Available from:. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1206575041711.
83. Department of health Immunisation against infectious disease: typhoid 2011, 287.
84. NaTHNaC Typhoid and paratyphoid 2008, [06/09/2012]. Available from:. http://www.nathnac.org/travel/factsheets/typhoid_paratyphoid.htm.
85. Engels E.A., Falagas M.E., Lau J., Bennish M.L. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 1998, 316(7125):110-116.
86. Report on certain enteric fever inoculation statistics. Br Med J 1904, 2(2288):1243-1246.
87. Cvjetanovic B., Uemura K. The present status of field and laboratory studies of typhoid and paratyphoid vaccines with special reference to studies sponsored by World Health Organization. Bull World Health Organ 1965, 32:29-36.
88. Stuhl L., Benda R., Frey N. A controlled field trial of the effectiveness of acetone- dried and inactivated and heat-phenol-inactivated typhoid vaccines in Yugoslavia. Bull World Health Organ 1964, 30:623-630.
89. A controlled field trial of the effectiveness of phenol and alcohol typhoid vaccines: final report. Bull World Health Organ 1962, 26(3):357-369.
90. Controlled field trials and laboratory studies on the effectiveness of typhoid vaccines in Poland, 1961-64. Bull World Health Organ 1966, 34(2):211-222.
91. FIELD and laboratory studies with typhoid vaccines: a preliminary report: Yugoslav Typhoid Commission. Bull World Health Organ 1957, 16(5):897-910.
92. Ashcroft M.T., Ritchie J.M., Nicholson C.C. Controlled field trial in British Guiana school children of heat-killed-phenolized and acetone-killed lyophilized typhoid vaccines. Am J Hyg 1964, 79:196-206.
93. Ashcroft M.T., Singh B., Nicholson C.C., Ritchie J.M., Sorryan E., Williams F. A seven- year field trial of two typhoid vaccines in Guyana. Lancet 1967, 2(7525):1056-1059.
94. Hejfec L.B., Salmin L.V., Lejtman M.Z., Kuz'minova M.L., Vasil'eva A.V., Levina L.A., et al. A controlled field trial and laboratory study of five typhoid vaccines in the USSR. Bull World Health Organ 1966, 34(3):321-339.
95. Tapa S., Cvjetanovic B. Controlled field trial on the effectiveness of one and two doses of acetone-inactivated and dried typhoid vaccine. Bull World Health Organ 1975, 52(1):75-80.
96. Wong K.H., Feeley J.C., Pittman M., Forlines M.E. Adhesion of Vi antigen and toxicity in typhoid vaccines inactivated by acetone or by heat and phenol. J Infect Dis 1974, 129(5):501-506.
97. Robbins J.D., Robbins J.B. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis 1984, 150(3):436-449.
98. Bodhidatta L., Taylor D.N., Thisyakorn U., Echeverria P. Control of typhoid fever in Bangkok, Thailand, by annual immunization of school children with parenteral typhoid vaccine. Rev Infect Dis 1987, 9(4):841-845.
99. Wong K.H., Feeley J.C., Northrup R.S., Forlines M.E. Vi antigen from Salmonella typhosa and immunity against typhoid fever. I. Isolation and immunologic properties in animals. Infect Immun 1974, 9(2):348-353.
100. Levine M.M. Typhoid vaccines ready for implementation. N Engl J Med 2009, 361(4):403-405.
101. Germanier R., Fuer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis 1975, 131(5):553-558.
102. Levine MM, Galen JE, Pasetti MF, Sztein MB. Attenuated strains of Salmonella enterica serovars typhi and paratyphi as live oral vaccines against enteric fever. p. 497-505.
103. Gilman R.H., Hornick R.B., Woodard W.E., DuPont H.L., Snyder M.J., Levine M.M., et al. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis 1977, 136(6):717-723.
104. Wahdan M.H., Serie C., Cerisier Y., Sallam S., Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis 1982, 145(3):292-295.
105. Levine M.M., Ferreccio C., Black R.E., Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987, 1(8541):1049-1052.
106. Levine M.M., Ferreccio C., Black R.E., Tacket C.O., Germanier R. Progress in vaccines against typhoid fever. Rev Infect Dis 1989, 11(Suppl. 3):S552-S567.
107. Olanratmanee T., Levine M., Losonsky G., Thisyakorn V., Cryz S.J. Safety and immunogenicity of Salmonella typhi Ty21a liquid formulation vaccine in 4- to 6- year-old Thai children. J Infect Dis 1992, 166(2):451-452.
108. Felix A., Krikorian K.S., Reitler R. The occurrence of typhoid bacilli containing Vi antigen in cases of typhoid fever and of Vi antibody in their sera. J Hyg (Lond) 1935, 35(3):421-427.
109. Wong K.H., Feeley J.C. Isolation of Vi antigen and a simple method for its measurement. Appl Microbiol 1972, 24(4):628-633.
110. Gotschlich E.C., Liu T.Y., Artenstein M.S. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med 1969, 129(6):1349-1365.
111. Tacket C.O., Ferreccio C., Robbins J.B., Tsai C.M., Schulz D., Cadoz M., et al. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis 1986, 154(2):342-345.
112. Tacket C.O., Levine M.M., Robbins J.B. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever. Vaccine 1988, 6(4):307-308.
113. Acharya I.L., Lowe C.U., Thapa R., Gurubacharya V.L., Shrestha M.B., Cadoz M., et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med 1987 Oct 29, 317(18):1101-1104.
114. Klugman K.P., Gilbertson I.T., Koornhof H.J., Robbins J.B., Schneerson R., Schulz D., et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987, 2(8569):1165-1169.
115. Sur D., Ochiai R.L., Bhattacharya S.K., Ganguly N.K., Ali M., Manna B., et al. A cluster- randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009, 361(4):335-344.
116. Black R.E., Levine M.M., Ferreccio C., Clements M.L., Lanata C., Rooney J., et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine 1990, 8(1):81-84.
117. Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res 2003, 338(23):2539-2547.
118. Landy M. Studies on Vi antigen. VI. Immunization of human beings with purified Vi antigen. Am J Hyg 1954, 60(1):52-62.
119. Levine M.M., Tacket C.O., Sztein M.B. Host-Salmonella interaction: human trials. Microbes Infect 2001, 3(14-15):1271-1279.
120. Pulickal A.S., Pollard A.J. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?. Expert Rev Vaccines 2007, 6(3):293-295.
121. Michel R., Garnotel E., Spiegel A., Morillon M., Saliou P., Boutin J.P. Outbreak of typhoid fever in vaccinated members of the French Armed Forces in the Ivory Coast. Eur J Epidemiol 2005, 20(7):635-642.
122. Froeschle J.E., Decker M.D. Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever. Vaccine 2010 Feb 3, 28(6):1451-1453.
123. Tacket C.O., Levine M.M. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis 2007, 45(Suppl. 1):S20-S23.
124. Parkhill J., Dougan G., James K.D., Thomson N.R., Pickard D., Wain J., et al. Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature 2001, 413(6858):848-852.
125. Holt K.E., Parkhill J., Mazzoni C.J., Roumagnac P., Weill F.X., Goodhead I., et al. High- throughput sequencing provides insights into genome variation and evolution in Salmonella typhi. Nat Genet 2008, 40(8):987-993.
126. Kirkpatrick B.D., McKenzie R., O'Neill J.P., Larsson C.J., Bourgeois A.L., Shimko J., et al. Evaluation of Salmonella enterica serovar typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 2006, 24(2):116-123.
127. Ochman H., Soncini F.C., Solomon F., Groisman E.A. Identification of a pathogenicity island required for Salmonella survival in host cells. Proc Natl Acad Sci U S A 1996, 93(15):7800-7804.
128. Coombes B.K., Wickham M.E., Lowden M.J., Brown N.F., Finlay B.B. Negative regulation of Salmonella pathogenicity island 2 is required for contextual control of virulence during typhoid. Proc Natl Acad Sci U S A 2005, 102(48):17460-17465.
129. Lyon C.E., Sadigh K.S., Carmolli M.P., Harro C., Sheldon E., Lindow J.C., et al. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7×10(10) colony- forming units. Vaccine 2010, 28(20):3602-3608.
130. Tran T.H., Nguyen T.D., Nguyen T.T., Ninh T.T., Tran N.B., Nguyen V.M., et al. A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. PLoS One 2010, 5(7):e11778.
131. Tacket C.O., Hone D.M., Losonsky G.A., Guers L., Edelman R., Levine M.M. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 1992, 10(7):443-446.
132. Johnson K., Charles I., Dougan G., Pickard D., O'Gaora P., Costa G., et al. The role of a stress-response protein in Salmonella typhimurium virulence. Mol Microbiol 1991, 5(2):401-407.
133. Salerno-Goncalves R., Wyant T.L., Pasetti M.F., Fernandez-Vina M., Tacket C.O., Levine M.M., et al. Concomitant induction of CD4+ and CD8+ T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA. J Immunol 2003, 170(5):2734-2741.
134. Tacket C.O., Sztein M.B., Wasserman S.S., Losonsky G., Kotloff K.L., Wyant T.L., et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun 2000 Mar, 68(3):1196-1201.
135. Klugman K.P., Koornhof H.J., Robbins J.B., Le Cam N.N. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996, 14(5):435-438.
136. Wang J.Y., Noriega F.R., Galen J.E., Barry E., Levine M.M. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infect Immun 2000, 68(8):4647-4652.
137. Tacket C.O., Pasetti M.F., Sztein M.B., Livio S., Levine M.M. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J Infect Dis 2004, 190(3):565-570.
138. Wahid R., Pasetti M.F., Maciel M., Simon J.K., Tacket C.O., Levine M.M., et al. Oral priming with Salmonella typhi vaccine strain CVD 909 followed by parenteral boost with the S. typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi- specific IgA and IgG B memory cells in humans. Clin Immunol 2011, 138(2):187-200.
139. Hohmann E.L., Oletta C.A., Miller S.I. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 1996, 14(1):19-24.
140. Hohmann E.L., Oletta C.A., Killeen K.P., Miller S.I. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996, 173(6):1408-1414.
141. An S.J., Yoon Y.K., Kothari S., Kim D.R., Kim J.A., Kothari N., et al. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine. Vaccine 2011 Dec 19.
142. Szu S.C., Stone A.L., Robbins J.D., Schneerson R., Robbins J.B. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med 1987, 166(5):1510-1524.
143. Szu S.C., Taylor D.N., Trofa A.C., Clements J.D., Shiloach J., Sadoff J.C., et al. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun 1994, 62(10):4440-4444.
144. Kossaczka Z., Lin F.Y., Ho V.A., Thuy N.T., Van Bay P., Thanh T.C., et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 1999 Nov, 67(11):5806-5810.
145. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 344(17):1263-1269.
146. van Damme P., Kafeja F., Anemona A., Basile V., Hilbert A.K., De Coster I., et al. Safety, immunogenicity and dose ranging of a new Vi-CRM(1)(9)(7) conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS One 2011, 6(9):e25398.
147. Thiem V.D., Lin F.Y., Canh do G., Son N.H., Anh D.D., Mao N.D., et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011, 18(5):730-735.
148. World Health Organisation Report of the meeting on typhoid fever, a neglected disease: towards a vaccine introduction policy 2007.
149. Mehta G., Arya S.C. Capsular Vi polysaccharide antigen in Salmonella enterica serovar typhi isolates. J Clin Microbiol 2002, 40(3):1127-1128.
150. Wain J., House D., Zafar A., Baker S., Nair S., Kidgell C., et al. Vi antigen expression in Salmonella enterica serovar typhi clinical isolates from Pakistan. J Clin Microbiol 2005, 43(3):1158-1165.
151. Arya S.C., Agarwal N. Re: typhoid fever vaccines: systematic review and meta- analysis of randomised clinical trials. Vaccine 2008, 26(3):291.
152. Ali A., An S.J., Cui C., Haque A., Carbis R. Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar typhi O-specific polysaccharides with diphtheria toxoid. Hum Vaccin Immunother 2012, 8(2):189-193.
153. Levine M.M., Ferreccio C., Black R.E., Lagos R., San Martin O., Blackwelder W.C. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 2007, 45(Suppl. 1):S24-S28.
154. Konadu E.Y., Lin F.Y., Ho V.A., Thuy N.T., Van Bay P., Thanh T.C., et al. Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide- tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 2000, 68(3):1529-1534.
155. Podda A., Saul A.J., Arora R., Bhutta Z., Sinha A., Gaind R., et al. Conjugate vaccines for enteric fever: proceedings of a meeting organized in New Delhi, India in 2009. J Infect Developing Countries 2010, 4(6):404-411.
156. Gat O., Galen J.E., Tennant S., Simon R., Blackwelder W.C., Silverman D.J., et al. Cell- associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella paratyphi A vaccines. PLoS Neglected Trop Dis 2011, 5(11):e1373.
157. Roland K.L., Tinge S.A., Kochi S.K., Thomas L.J., Killeen K.P. Reactogenicity and immunogenicity of live attenuated Salmonella enterica serovar paratyphi A enteric fever vaccine candidates. Vaccine 2010, 28(21):3679-3687.
158. Woodward W.E. Volunteer studies of typhoid fever and vaccines. Trans R Soc Trop Med Hyg 1980, 74(5):553-556.
159. Sprinz H., Gangarosa E.J., Williams M., Hornick R.B., Woodward T.E. Histopathology of the upper small intestines in typhoid fever. Biopsy study of experimental disease in man. Am J Dig Dis 1966, 11(8):615-624.
160. Dupont H.L., Hornick R.B., Snyder M.J., Dawkins A.T., Heiner G.G., Woodward T.E. Studies of immunity in typhoid fever. Protection induced by killed oral antigens or by primary infection. Bull World Health Organ 1971, 44(5):667-672.
161. Wright A.E. Association of serous haemorrage with conditions of defective blood coagulability. Lancet Sept. 19 1896, 807.
162. Hornick R.B., Woodward T.E. Appraisal of typhoid vaccine in experimentally infected human subjects. Trans Am Clin Climatol Assoc 1967, 78:70-78.
163. Hornick R.B., Greisman S.E., Woodward T.E., DuPont H.L., Dawkins A.T., Snyder M.J. Typhoid fever: pathogenesis and immunologic control. N Engl J Med 1970, 283(13):686-691.
164. Peter G., des Vignes-Kendrick M., Eickhoff T.C., Fine A., Galvin V., Levine M.M., et al. Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee. Pediatrics 1999, 104(4 Pt 1):942-950.
165. Kirkpatrick B.D., Tenney K.M., Larsson C.J., O'Neill J.P., Ventrone C., Bentley M., et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J Infect Dis 2005, 192(3):360-366.